Global Blood Therapeutics, Inc. (GBT), is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. More »

Featured News

Recent News

12/07/18Global Blood Therapeutics Prices a $150.0 Million Common Stock Public Offering
12/06/18Global Blood Therapeutics Announces Proposed Public Offering of Common Stock
12/04/18GBT Announces New Employment Inducement Grants
12/03/18GBT Announces Positive 24-week Results from Phase 3 HOPE Study Demonstrating Clinically and Statistically Significant Improvements in Hemoglobin and Clinical Measures of Hemolysis and a Favorable Safety Profile

More »

Media Resources

Stay Informed

Sign up to receive email updates about ongoing sickle cell disease clinical studies, awareness and educational information and GBT news at:

Media Contact

Stephanie Yao